创新药概念早盘高开 新开源披露注射用人白介素-2获批临床

Group 1 - The core viewpoint of the news is that XinKaiYuan's stock price surged due to the announcement of a clinical trial approval for a new drug, LYC001, developed by its affiliate, marking a significant milestone in innovative drug development [1][3] - XinKaiYuan's stock price reached 19.18 yuan per share, approaching the daily limit, and closed with an increase of over 3% [1] - The drug LYC001, a high-affinity complex, is the first of its kind globally to utilize a novel drug delivery technology through the lymphatic system, addressing issues of stability and specificity in existing large molecule drugs [1][2] Group 2 - The clinical trial approval for LYC001 is a key milestone for the company, as it is part of a national key research and development program focused on innovative drug technology for common diseases [1][3] - The drug demonstrates significant advantages, including improved solubility and stability of interleukin-2, with a biological availability exceeding 90% when administered subcutaneously [2] - XinKaiYuan holds a 23.81% stake in the affiliate, and the progress in drug development is expected to strengthen its competitive position in the precision medicine sector [3]